The goal of this phase 1 prospective multicenter trial was to determine the maximum tolerated dose (MTD) of MB-CART2019.1 in 12 adult patients with CD20- and CD19-positive r/r B-NHL, based on DLTs. Here, CD19 is linked to non-Hodgkin lymphoma.